These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 23630239)

  • 1. Drug patents: the evergreening problem.
    Collier R
    CMAJ; 2013 Jun; 185(9):E385-6. PubMed ID: 23630239
    [No Abstract]   [Full Text] [Related]  

  • 2. Limiting "evergreening" for a better balance of drug innovation incentives.
    Stanbrook MB
    CMAJ; 2013 Aug; 185(11):939. PubMed ID: 23877665
    [No Abstract]   [Full Text] [Related]  

  • 3. Drug patents: innovation v. accessibility.
    Collier R
    CMAJ; 2013 Jun; 185(9):E379-80. PubMed ID: 23630237
    [No Abstract]   [Full Text] [Related]  

  • 4. India's patent laws under pressure.
    Roderick P; Pollock AM
    Lancet; 2012 Sep; 380(9846):e2-4. PubMed ID: 22988579
    [No Abstract]   [Full Text] [Related]  

  • 5. How Patent Troll Legislation Can Increase Timely Access to Generic Drugs.
    Treasure CL; Kesselheim AS
    JAMA Intern Med; 2016 Jun; 176(6):729-30. PubMed ID: 27183456
    [No Abstract]   [Full Text] [Related]  

  • 6. Supreme Court rules against drug patent "evergreening".
    Kondro W
    CMAJ; 2006 Dec; 175(12):1508-9. PubMed ID: 17146081
    [No Abstract]   [Full Text] [Related]  

  • 7. A generic problem.
    Hanauer SB
    Nat Clin Pract Gastroenterol Hepatol; 2006 Dec; 3(12):649. PubMed ID: 17130869
    [No Abstract]   [Full Text] [Related]  

  • 8. Intellectual property. Challenges to India's pharmaceutical patent laws.
    Sampat BN; Shadlen KC; Amin TM
    Science; 2012 Jul; 337(6093):414-5. PubMed ID: 22767892
    [No Abstract]   [Full Text] [Related]  

  • 9. Taking TRIPS to India--Novartis, patent law, and access to medicines.
    Mueller JM
    N Engl J Med; 2007 Feb; 356(6):541-3. PubMed ID: 17287473
    [No Abstract]   [Full Text] [Related]  

  • 10. Patents: a threat to innovation?
    Manocaran M
    Science; 2010 Jan; 327(5961):31-2; author reply 32. PubMed ID: 20044557
    [No Abstract]   [Full Text] [Related]  

  • 11. India's patent case victory rattles Big Pharma.
    Chatterjee P
    Lancet; 2013 Apr; 381(9874):1263. PubMed ID: 23589911
    [No Abstract]   [Full Text] [Related]  

  • 12. India's new patent bill threatens generic industry.
    Ahmad K
    Lancet Infect Dis; 2005 May; 5(5):265. PubMed ID: 15889471
    [No Abstract]   [Full Text] [Related]  

  • 13. Staving off death: a case study of the pharmaceutical industry's strategies to protect blockbuster franchises.
    Gorlin DI
    Food Drug Law J; 2008; 63(4):823-64. PubMed ID: 19601385
    [No Abstract]   [Full Text] [Related]  

  • 14. Old drugs, new uses: solving a Hatch-Waxman patent predicament.
    McPhie DC
    Food Drug Law J; 2004; 59(1):155-68. PubMed ID: 15190929
    [No Abstract]   [Full Text] [Related]  

  • 15. High Court strikes down Merck's patent on alendronate.
    Dyer O
    BMJ; 2003 Feb; 326(7383):243. PubMed ID: 12560269
    [No Abstract]   [Full Text] [Related]  

  • 16. Intellectual property. Balancing innovation and access: patent challenges tip the scales.
    Higgins MJ; Graham SJ
    Science; 2009 Oct; 326(5951):370-1. PubMed ID: 19833944
    [No Abstract]   [Full Text] [Related]  

  • 17. US policy may encourage counterfeit drugs.
    Bouchie A
    Nat Biotechnol; 2003 Feb; 21(2):121. PubMed ID: 12560826
    [No Abstract]   [Full Text] [Related]  

  • 18. The emerging effects of the Drug Price Competition and Patent Term Restoration Act of 1984.
    Lewis RA
    J Contemp Health Law Policy; 1992; 8():361-78. PubMed ID: 10118987
    [No Abstract]   [Full Text] [Related]  

  • 19. Potential pathways for abbreviated approval of generic biologics under existing law and proposed reforms to the law.
    Dinh TQ
    Food Drug Law J; 2007; 62(1):77-137. PubMed ID: 17444027
    [No Abstract]   [Full Text] [Related]  

  • 20. The Drug Price Competition and Patent Term Restoration Act of 1984: fine-tuning the balance between the interests of pioneer and generic drug manufacturers.
    Soehnge H
    Food Drug Law J; 2003; 58(1):51-80. PubMed ID: 12739584
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.